Literature DB >> 18764722

Agents in development for the treatment of diabetic nephropathy.

Su-Yen Goh1, Mariusz Jasik, Mark E Cooper.   

Abstract

BACKGROUND: Nephropathy is a major cause of morbidity and mortality in diabetic patients. Current treatments include optimization of glycemic and blood pressure control, but more innovative strategies are needed for the prevention and treatment of diabetic nephropathy.
OBJECTIVES: To review emerging therapies for diabetic nephropathy.
METHODS: This paper discusses the molecular mechanisms of diabetic nephropathy and the potential therapeutic interventions. RESULTS/
CONCLUSION: New therapies, including those targeting the accumulation of advanced glycation end products (AGEs) and reactive oxygen species (ROS) generation, are likely to feature in future treatment regimens. Other approaches that at this stage do not appear to be progressing include the glycosaminoglycan sulodexide and the protein kinase C-beta (PKC-beta) inhibitor, ruboxistaurin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18764722     DOI: 10.1517/14728214.13.3.447

Source DB:  PubMed          Journal:  Expert Opin Emerg Drugs        ISSN: 1472-8214            Impact factor:   4.191


  8 in total

1.  Nebivolol attenuates redox-sensitive glomerular and tubular mediated proteinuria in obese rats.

Authors:  Javad Habibi; Melvin R Hayden; James R Sowers; Lakshmi Pulakat; Roger D Tilmon; Camila Manrique; Guido Lastra; Vincent G Demarco; Adam Whaley-Connell
Journal:  Endocrinology       Date:  2010-12-22       Impact factor: 4.736

Review 2.  Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy.

Authors:  Judit Gordon; Jeffrey B Kopp
Journal:  Adv Chronic Kidney Dis       Date:  2011-07       Impact factor: 3.620

3.  Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered.

Authors:  Antonio V Gaddi; Arrigo Fg Cicero; Giovanni Gambaro
Journal:  Int J Nephrol Renovasc Dis       Date:  2010-07-06

4.  Preclinical and clinical evidence of nephro- and cardiovascular protective effects of glycosaminoglycans.

Authors:  Arrigo F Cicero; Sibel Ertek
Journal:  Arch Med Sci       Date:  2010-09-07       Impact factor: 3.318

Review 5.  Complexity of diabetic nephropathy pathogenesis and design of investigations.

Authors:  Majid Tavafi
Journal:  J Renal Inj Prev       Date:  2013-06-01

Review 6.  Comprehensive approach to diabetic nephropathy.

Authors:  Bancha Satirapoj; Sharon G Adler
Journal:  Kidney Res Clin Pract       Date:  2014-09-10

7.  Drug repurposing: In-vitro anti-glycation properties of 18 common drugs.

Authors:  Saima Rasheed; Sara S Sánchez; Sammer Yousuf; Stella M Honoré; M Iqbal Choudhary
Journal:  PLoS One       Date:  2018-01-04       Impact factor: 3.240

8.  Oat Protects against Diabetic Nephropathy in Rats via Attenuating Advanced Glycation End Products and Nuclear Factor Kappa B.

Authors:  Abdulrahman L Al-Malki
Journal:  Evid Based Complement Alternat Med       Date:  2013-10-10       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.